Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven for PNALD
NCT04697888Phase 3Completed
- Sponsor
- Children's Mercy Kansas City
- Start
- Apr 2013
- Primary completion
- Nov 2018
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of eicosapentaenoic acid + docosahexaenoic acid in Parenteral Nutrition Associated Liver Disease (PNALD), sponsored by Children's Mercy Kansas City. Started Apr 2013; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD)
Beyond the preview
Go deeper on NCT04697888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697888.